Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study

Abstract

Persistent use of bisphosphonates decreases the risk of osteoporotic fractures in clinical practice. Approximately 6% of fractures among users of bisphosphonates could be prevented if persistence was improved by 20%. However, current persistence with bisphosphonate therapy is suboptimal and strategies that further increase persistence are likely to further prevent the number of fractures.

Association Between Gastrointestinal Events and Persistence with Osteoporosis Therapy: Analysis of Administrative Claims of a U.S. Managed Care Population

“…15,[18][19][20][21][22][23] Multiple studies indicate that medication side effects may be one of the key factors influencing patients' suboptimal treatment persistence and adherence behavior. [24][25][26] Gastrointestinal (GI) events are common among patients receiving bisphosphonate therapy for the treatment of osteoporosis.…”

“…[12][13][14] Additionally, many patients started on osteoporosis medication do not persist with treatment. 9,10,[15][16][17] Approximately 50% or more of patients newly started on bisphosphonates discontinue treatment within 12…”

Adherence to treatment with denosumab, its efficacy and safety in women with postmenopausal osteoporosis in clinical practice

“…Несоблюдение рекомендаций по длитель-ности лечения и режима дозирования увеличивает риск пе-реломов у пациентов с ОП на 17-39% [1][2][3]. Привержен-ность лечению пероральными бисфосфонатами достаточно низкая: почти 2/3 пациентов прекращают лечение в течение первого года после назначения терапии [3,4].…”

“…Несоблюдение рекомендаций по длитель-ности лечения и режима дозирования увеличивает риск пе-реломов у пациентов с ОП на 17-39% [1][2][3]. Привержен-ность лечению пероральными бисфосфонатами достаточно низкая: почти 2/3 пациентов прекращают лечение в течение первого года после назначения терапии [3,4]. Частота, с ко-торой принимается препарат, также может влиять на при-верженность больных терапии, что было показано в не-скольких исследованиях [5,6].…”

Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial

“…This nonadherence has significant consequences; patients noncompliant with anti-osteoporosis treatment (such as bisphosphonates) have an increased fracture risk. [25,26].…”